NSE: ABBOTINDIA | BSE: 500488

Falling Comet

Download real time

26295.00 -100.00 (-0.38%)

New 52W Low in past week

7,946 NSE+BSE Volume

NSE 20 Feb, 2026 3:31 PM (IST)

55,875

Market Cap

High in industry

Beta 1Year

Very Low volatility

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Search Inside the pdf :

Abbott India Ltd.

13 Feb 2026

26295.00

-0.38%

Abbott India

Buy: Abbott India Ltd.

Target

ICICI Direct

New introduction tempo also maintained- Overall growth continues to be driven by legacy power brands (top 10 brands CAGR ~10% between January 23-26 despite slowdown in Mixtard and Novomix) and traction in few brands from the marketed portfolio. The company remains a standout performer among MNCs on the back of new products launch trajectory (+100 launches in the last 12 years and another 75 planned for the next 5 years) and performance consistency in most of the legacy brands. In FY25, the company introduced 7 new brands- Citrosoda UTI, Digene Insta,...

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

27 Nov 2025

26295.00

-0.38%

Abbott India (BUY): Visibility of margin improvement

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Mixtard 50 injectables off the shelf from Aug'25, yet monthly sales were Rs705 mn inAug'25, 762 mn in Sep'25 and Rs 710 mn in Oct'25

Abbott has lost -20.47% in the last 6 Months

Abbott India Ltd.

09 Nov 2025

26295.00

-0.38%

Operational leverage at play

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q2FY26 revenue grew at a modest pace of 7.6% YoY. We believe moderation in growth was mainly due to discontinuation of insulin pens for Human Mixtard, Levemir and Xultophy by Novo Nordisk in India as it prioritises capacity for GLP-1 brands Ozempic and Wegovy.

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

08 Nov 2025

26295.00

-0.38%

Abbott India

Buy: Abbott India Ltd.

Recommendation Target

ICICI Direct

Q2FY26- Decent print driven by growth in some power brands- Revenues grew ~8% YoY to 1757 crore. As per IQVIA, some of the power brands such as Thyronorm (Hormonal), Udiliv (GI), Cremaffin Plus (GI) and Duphalac (GI) witnessed decent growth along with some marketed brands of Novo Nordisk and Abbott Healthcare such as Rybelsus (Semaglutide) and Ryzodeg (Insulin). While Mixtard (Insulin) and Novomix (Anti-Diabetic) registered de-growth during the quarter. EBITDA grew ~14% YoY to 502...

Abbott India Ltd. has an average target of 35280.00 from 4 brokers.

Abbott India Ltd.

07 Nov 2025

26295.00

-0.38%

Abbott India (BUY): Robust profitability amid GLP1 wave

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Sales reported 1.3% below while EBITDA/PAT reported 4.5%/6.4% above our estimates. EBITDA margin was 160 bps higher estimates

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

17 Sep 2025

26295.00

-0.38%

Steady business, outpacing Pharma peers

Buy: Abbott India Ltd.

Target

Sharekhan

Strong history of product launches: Abbott India has been steadily growing led by consistent launches of both - own and Novo Nordisk’s products (marketing). Abbott India has launched over 100 products in India in the last 12 years and we expect the pipeline to stay strong.

Abbott India Ltd. has an average target of 35280.00 from 4 brokers.

Abbott India Ltd.

12 Aug 2025

26295.00

-0.38%

Abbott India (BUY): Good traction in Wegovy sales

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Sales in-line; EBITDA/PAT lower vs our estimates. EBITDA margin reported at 25.6%; core portfolio EBITDA margin was at 36.7%

Abbott India Ltd. has an average target of 35280.00 from 4 brokers.

Abbott India Ltd.

04 Jul 2025

26295.00

-0.38%

Abbott India (BUY): Ascribing valuation in line with its peer GSK

Buy: Abbott India Ltd.

Target

BOB Capital Markets Ltd.

Novo's oral semaglutide Rybelsus is growing at a robust 173% CAGR over a 3Y period to Rs 4bn, as on MAT MAY'25

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

16 May 2025

26295.00

-0.38%

Sustained improvement across the board

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) revenue grew 12% YoY ahead of most MNCs (avg. growth of ~10% YoY and IPM growth of ~8% YoY in Q4FY25). Abbott’s growth was aided by healthy traction in its own brands along with key brands of Novo Nordisk like Rybelsus and Ryzodeg.